LTRN Q3 2025 Earnings — Lantern Pharma Inc. Revenue & Financial Results | Market Cap Arena

LTRNLantern Pharma Inc.

$31M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$4,102

Operating Income

-$4M

Net Income

-$4M

EPS (Diluted)

$-0.39

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$143,685

Balance Sheet

Total Assets

$14M

Total Liabilities

$4M

Stockholders' Equity

$10M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$4,102	$0	—
Operating Income	-$4M	-$5M	+16.0%
Net Income	-$4M	-$5M	+7.3%